
    
      This study has a screening period (up to 3±2 days duration). Randomization will be held in
      each stratum (H. pylori-positive and H. pylori-negative) on the Visit 1. Treatment period
      will consist of 2 visits: Visit 2 (up to 14±2 days after Visit 1) in subjects with completely
      healed ulcer(s) and erosions after control esophagogastroduodenoscopy (EGDS) and Visit 3 (up
      to 28±2 days after Visit 1) in subjects with not healed ulcers and erosions after control
      EGDS on Visit 2. The period of follow-up safety assessments will last 1 week after the end of
      the study treatment
    
  